Hydroxychloroquine retinopathy after short-term therapy

Retinal Cases and Brief Reports

Volumn 8, Issue 1, 2014, Pages 67-69

  Phillips, Brandon N ^a   Chun, Dal W ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Hydroxychloroquine toxicity; Plaquenil; Retinopathy

Indexed keywords

HYDROXYCHLOROQUINE; IBUPROFEN; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; AUTOFLUORESCENCE; CASE REPORT; DRUG MEGADOSE; DRUG TOXICITY; EYE FUNDUS; FEMALE; HUMAN; HUMPHREY PERIMETER; OBSERVATIONAL STUDY; OPHTHALMOLOGY; OPTICAL COHERENCE TOMOGRAPHY; RETINA FOVEA; RETINA MACULOPATHY; RETINA ROD OUTER SEGMENT; RETINOPATHY; RHEUMATOID ARTHRITIS; RISK FACTOR; SHORT COURSE THERAPY; VISUAL FIELD; VISUAL IMPAIRMENT; CHEMICALLY INDUCED; MIDDLE AGED; RETINA DISEASE; VISUAL DISORDER;

ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MIDDLE AGED; RETINAL DISEASES; VISION DISORDERS;

EID: 84898048367     PISSN: 19351089     EISSN: 19371578     Source Type: Journal    
DOI: 10.1097/ICB.0000000000000006     Document Type: Article

References (7)

1. Bernstein H, Ginsberg J. The pathology of chloroquine retinopathy. Arch Opthalmol 1964;71:238-245.
2. Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol 2011;129:30-39.
3. Sundelin S, Terman A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS 2002;110:481-489.
4. Marmor MF, Kellner U, Lai TY, et al; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011;118:415-422.
5. Schraermeyer U, Peters S, Thumann G, et al. Melanin granules of retinal pigment epithelium are connected with the lysosomal degradation pathway. Exp Eye Res 1999;68:237-245.
6. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996;5:S11-S15.
7. Hedner T, Samulesson O, Währborg P, et al. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs 2004;64:2315-2343; discussion 2344-5.